# GT Biopharma, Inc.

GT Biopharma, Inc. is an other based in San Francisco, United States.

## Overview

- **Organization type:** other
- **Headquarters:** San Francisco, United States
- **Region:** North America
- **Address:** San Francisco, CA, United States
- **Founded:** 1997
- **Assets under management:** Undisclosed
- **Website:** gtbiopharma.com
- **LinkedIn:** https://www.linkedin.com/company/gtbiopharma

## Regulatory record

- **Reports private funds:** No

## About

GT Biopharma, Inc. was founded in 1997 and is headquartered in San Francisco, California. The company operates as a clinical-stage biotechnology firm, with CEO Anthony Cataldo leading from 2011 onward. Its wealth origin is not publicly disclosed. The firm's strategy centers on immuno-oncology, specifically NK cell-directed therapies. Their lead candidate targets CD16 activation to treat hematologic malignancies. GT Biopharma partners with the National Cancer Institute and other academic institutions for research (per SEC filings, 2023). GT Biopharma has not disclosed team size or AUM. The firm maintains no known adjacent vehicles. As of 2025, it continues to advance its pipeline through Phase 1/2 trials, with no revenue from approved products. The structural differentiator is its public-company status: GT Biopharma trades on the NASDAQ under ticker GTBP. This allows capital access via equity markets, distinct from private biotechs.

## Sectors

- Biotechnology
- Immuno-Oncology
- Drug Development

## People

- Anthony Cataldo — Chief Executive Officer
- Dr. Raymond Urbanski — Chief Medical Officer

## Questions

### Who runs GT Biopharma?

Anthony Cataldo serves as CEO. Dr. Raymond Urbanski is Chief Medical Officer (per SEC filings, 2023).

### What is GT Biopharma's drug pipeline?

The lead candidate GTB-3550 is a bispecific NK cell engager targeting CD16 and CD33 for acute myeloid leukemia and high-risk myelodysplastic syndromes, currently in Phase 1/2 trials (per SEC filings, 2024).

### Is GT Biopharma publicly traded?

Yes, the firm trades on the NASDAQ under ticker GTBP (public record).

### Does GT Biopharma generate revenue?

No, as a clinical-stage biotech, it has no approved products; revenue is minimal (per SEC filings, 2024).

### How is GT Biopharma funded?

Funding comes from public equity markets and occasional financings (per SEC filings, 2023).

## Related profiles

- [Huachen AI Parking Management Technology Holding Co., Ltd](https://altss.com/profile/huachen-ai-parking-management-technology-holding-co-ltd)
- [MetaVia](https://altss.com/profile/metavia-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/gt-biopharma-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology